7 / 36
Crizotinib
(n=172
a
)
Pemetrexed
(n=99
a
)
Docetaxel
(n=72
a
)
Median, mo
7.7
4.2
2.6
HR
b
(95% CI)
0.59 (0.43 to 0.80)
0.30 (0.21 to 0.43)
P
<0.001
<0.001
Probability of survival without
progression (%)
100
80
60
40
20
0
0
5
10
15
20
25
Time (months)
172
93
38
11
2
0
99
36
2
3
1
0
72
13
3
1
0
No. at risk
Crizotinib
Pemetrexed
Docetaxel
Profile 1007
PFS Crizotinib vs Pemetrexed vs Docetaxel
Shaw AT, et al. N Engl J Med 2013;368:2385–94
Endpoint
ORR %
65%
Median PFS
7.7 months
Median duration of response
8.0 months